Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Delivery of biologics to the lung
Autore:
Cipolla, D; Farr, S; Gonda, I; Otulana, B;
Indirizzi:
Aradigm Corp, Hayward, CA 94545 USA Aradigm Corp Hayward CA USA 94545Aradigm Corp, Hayward, CA 94545 USA
Titolo Testata:
NEW DRUGS FOR ASTHMA, ALLERGY AND COPD
, volume: 31, anno: 2001,
pagine: 20 - 23
SICI:
1422-2140(2001)31:<20:DOBTTL>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYSTIC-FIBROSIS; AEROSOL; INTRAPULMONARY; DEPOSITION; THERAPY; IGE;
Tipo documento:
Article
Natura:
Collana
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Gonda, I Aradigm Corp, 3929 Point Eden Way, Hayward, CA 94545 USA Aradigm Corp 3929 Point Eden Way Hayward CA USA 94545 A 94545 USA
Citazione:
D. Cipolla et al., "Delivery of biologics to the lung", PROG R RES, 31, 2001, pp. 20-23

Abstract

Delivery of drugs by inhalation for the treatment of respiratory disease is well established. The primary advantage of local delivery is the achievement of efficacy while minimizing systemic side effects. With the respiratory tract as the target organ, biologics are likely to benefit even more by direct delivery because their transport between the blood circulation and the airway tissue and lumen is limited. This may result in better safety and efficacy, as well as improved economics since much lower doses may be effective compared to systemic administration. Protecting biologies against degradation during storage and aerosol generation may require the use of new types of formulations and inhalation systems with which they can be efficiently and reproducibly delivered. Examples of current clinical status of biologics delivered to the lung are provided.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 09:35:32